This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

AMR & Sustainability

Pfizer’s commitment to a sustainable future

A strong pipeline of new antibiotics is essential to restoring the balance against increasing rates of AMR. However, investing in antibiotic research has long been unattractive for life science companies and no new class of antibiotics has been invented for decades.1

The journey from discovery to a clinically approved medicine is long and failure rate is high. The complexity and uncertainty in the early stages of discovery mean that huge sums have to be invested before a new antibiotic is successfully developed. New medicines may be kept in reserve for later use and therefore used infrequently, making it difficult to recover the high costs associated with development.2

At Pfizer, we’re committed to working with the UK Government, Department of Health and Social Care and other policy makers to develop a new model which ensures appropriate use of antibiotics, reduces the financial impact of infections and outbreaks and encourages a more sustainable economic model.

EEPRU developed and proposed a new framework which should be the basis of a value assessment for antibiotics, including additional elements of value such as: Diversity-, Insurance-, Enablement-, Transmission and Spectrum- value which are not typically included in traditional Health Technology Assessment (HTA) frameworks.

Building off this framework Pfizer developed a model that captures not only those criteria that are routinely included in HTA frameworks (Direct health costs & effects), but also several of the additional value elements outlined by EEPRU, including: Transmission- and Diversity value by modelling the dynamics of infection and resistance within the wider population with a flexible treatment pathway. While this model is not proposed to be the only way forward we believe it will help accelerate the thinking required to continue to progress. The model has been shared widely across industry, presented via the APBI collaboration and discussed with EEPRU. The model is also available online, having been published through PharmacoEconomics.


Dynamic Disease Transmission Model 

Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model 

View the publication
References:
  1. Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. May 2016. Available at: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf [Last Accessed July 2020]
  2. ABPI response to details of new payment system for antibiotics. July 2019. Available at: https://www.abpi.org.uk/media-centre/news/2019/july/abpi-response-to-details-of-new-payment-system-for-antibiotics/ [Last Accessed July 2020]​
PP-AIP-GBR-0803. September 2021

Educational Resources

We have a variety of educational resources aimed at supporting Healthcare Professsionals looking to enhance their knowledge of AMR and Stewardship.

Access resources

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No